Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
| Study Name | |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT05285358 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| City of Hope Comprehensive Cancer Center | |
| Institution Address | |
| 1500 East Duarte Road | |
| City | |
| Duarte | |
| State | |
| California | |
| Zip Code | |
| 91010 | |
| Country | |
| United States | |
| Phone | |
| 626-471-9200 | |
| Study Contacts | |
| Principal Investigator | |
| Daneng Li | |
| P.I. Phone | |
| (626) 471-9200 | |
| P.I. Email | |
| danli@coh.org | |
| List additional Principal Investigators (include phone number and email) | |
| Mustafa Raoof, MD 626-471-9200 mraoof@coh.org |
|
| Study Coordinator | |
| NA | |
| Study Coordinator Phone | |
| (000) 000-0000 | |
| Study Coordinator Email | |
| danli@coh.org | |
| OVERVIEW – in layman’s terms (150 words max) | |
| This phase I trial studies the side effects and effect of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel in combination with gemcitabine and cisplatin in treating patients with biliary tract cancer that has spread to the peritoneum (peritoneal metastases). | |
| Enrollment | |
| 12 | |
| Study Start Date | |
| 07/11/2022 | |
| Estimated Completion Date | |
| 03/07/2024 | |